Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
Polymer drug conjugates composed of N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer covalently bound doxorubicin, and containing additionally galactosamine to facilitate hepatocyte-specific targeting (HPMA copolymer-dox-gal), were synthesised to contain a small amount (approximately 1 mol%) of the monomer methacryloyltyrosinamide to permit radioiodination with [123I]iodide. After intravenous administration to both normal mice and nude mice bearing hepatic human colon carcinoma, the biodistribution of the conjugate was monitored using the gamma camera, and also by dissection analysis. Efficient liver accumulation of HPMA copolymer-dox-gal was seen in the gamma camera images within 20 min, both in normal and tumour-bearing animals. Quantitatively liver uptake was approximately 40% dose administered/g liver. Images of the tumour-bearing animals showed clearly a much lower accumulation of HPMA copolymer-dox-gal in the colon carcinoma deposits within the liver (3-9% dose/g tumour), and this lack of uptake was verified by ex vivo imaging of the tumour-containing liver and also by dissection analysis. It can be concluded that 123I-labelled HPMA copolymer conjugates offer great potential as effective imaging agents and can be used for future non-invasive clinical studies. This nuclear imaging method will enable optimisation of the dosing schedule by identification of doses of HPMA copolymer-dox-gal that display receptor saturation (and hence diminished targeting efficiency). In addition this conjugate can provide negative images of liver-associated tumour deposits that do not express the asialoglycoprotein receptor.
Pimm
M V
MV
Cancer Research Laboratories, University of Nottingham, UK.
Perkins
A C
AC
Strohalm
J
J
Ulbrich
K
K
Duncan
R
R
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000378:metabolism / Q000627:therapeutic use*; D001665:Binding Sites; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism* / Q000648:ultrastructure; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000648:ultrastructure; D004317:Doxorubicin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D005688:Galactosamine / Q000378:metabolism*; D005720:Gamma Rays; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000648:ultrastructure; D008689:Methacrylates / Q000378:metabolism* / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011877:Radionuclide Imaging; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D007457:Iodine Radioisotopes; D008689:Methacrylates; D005688:Galactosamine; D004317:Doxorubicin; C032802:hydroxypropyl methacrylate